Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial

Phase 2positivePositive

AI Analysis

Summary

Arrowhead's tau-targeting Alzheimer's disease therapy demonstrated tau reduction in Phase I/IIa trials and is advancing from healthy volunteer studies to patient populations.

Clinical Trial Data

Phase

Phase I/IIa

Primary Endpoint

Met

Outcome Details

tau reduction demonstrated in Phase I/IIa trial

Importance:6/10

Sentiment:

0.70

Alzheimer's diseasetau-targetingclinical trial progressionPhase I/IIa

Related Companies

$ARWR

Read the original article

Published by Clinical Trials Arena on October 14, 2026 4:21 PM

Read Original